## Gene Summary
CYP19A1, also known as aromatase, is a crucial enzyme in the biosynthesis of estrogens from androgens. It catalyzes the conversion of androstenedione to estrone and testosterone to estradiol. CYP19A1 is prominently expressed in the gonads (ovaries and testes), adipose tissue, and the brain, playing a fundamental role in sexual development and reproduction. The gene's expression and activity are subject to regulation by various hormonal and tissue-specific factors.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CYP19A1 is pivotal in estrogen biosynthesis, making it a key target in the treatment of estrogen-dependent conditions such as breast cancer, endometriosis, and osteoporosis. Inhibited by drugs like anastrozole, letrozole, and exemestane, these medications are commonly used in hormone therapy for breast cancer. Conditions such as aromatase excess syndrome and aromatase deficiency are linked to mutations in CYP19A1, manifesting as hyperestrogenism or hypogonadism, respectively. CYP19A1's activity also influences bone growth, adipose distribution, and fertility.

## Pharmacogenetics
Pharmacogenetics reveals significant associations between variations in the CYP19A1 gene and the efficacy and tolerability of aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane. Genetic polymorphisms in CYP19A1 can influence the plasma levels of estrogen, impacting the outcome and side effects of AI-based therapies in breast cancer patients. A notable polymorphism, rs4646, has been studied for its role in altering the response to these drugs, potentially affecting treatment outcomes. Understanding individual genetic profiles can guide the personalization of therapy, emphasizing dose adjustments and choice of treatment in managing estrogen-mediated conditions.